Kozenis (tafenoquine) approved by the Australian TGA for the radical cure of P. vivax malaria
Approval marks a major step in global eradication efforts and will support registrations in malaria-endemic countries
Press releases
These press releases are intended for business journalists and analysts/investors
GSK Australia commits to new Reconciliation Action Plan
Read more - GSK Australia commits to new Reconciliation Action Plan Read more
Doctors encouraging middle-aged Aussie blokes to consider their prostate
Read more - Doctors encouraging middle-aged Aussie blokes to consider their prostate Read more
Australia responds to changing humanitarian need with pioneering new health education course
New treatment reimbursed for major breathing disorder
Trelegy Ellipta (fluticasone furoate, umeclidinium and vilanterol) - first, once-daily triple therapy for COPD reimbursed by the PBS in Australia
Read more - New treatment reimbursed for major breathing disorder Read more
GSK statement on influenza vaccine supply for the 2018 season
Read more - GSK statement on influenza vaccine supply for the 2018 season Read more
Nominations open for prestigious GSK Award for Research Excellence
- 38th year of $80,000 research grant
Read more - Nominations open for prestigious GSK Award for Research Excellence Read more
Simon Dingemans, Chief Financial Officer, to retire from GSK
Read more - Simon Dingemans, Chief Financial Officer, to retire from GSK Read more
GSK Australia reports 2017 results to ASIC
Read more - GSK Australia reports 2017 results to ASIC Read more
GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER
Read more - GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER Read more